Loading…
Swift Digital Group LLC dba Swadesii was cited for offering ten unapproved new drug products for sale in the United States, including thyroid tablets, syrups, homeopathic remedies, and eye drops, in violation of sections 301(d) and 505(a) of the Federal Food, Drug, and Cosmetic Act. The products bore labeling claims to cure, mitigate, treat, or prevent serious and life-threatening conditions including measles, cancer, diabetes, stroke, Alzheimer's disease, and hepatitis—conditions for which FDA-approved safe and effective treatments exist. The FDA expressed particular concern that consumers relying on these unapproved products might forgo, delay, or discontinue proven medical treatments, and noted that ophthalmic products pose heightened risk due to direct eye administration bypassing natural bodily defenses.